Current Status of Multiple Drug Molecules, and Vaccines: An Update in SARS-CoV-2 Therapeutics

Ramesh Kandimalla, Albin John, Chandrika Abburi, Jayalakshmi Vallamkondu, P. Hemachandra Reddy

    Research output: Contribution to journalReview articlepeer-review

    38 Scopus citations


    The coronavirus disease of 2019 (COVID-19) is a pandemic disease that has taken the lives of many around the world. It is caused by severe acute respiratory syndrome-corona virus-2 (SARS-CoV-2). To date, the USA, Italy, Spain, France, Russia, and the UK have been hit the hardest by the virus. However, death counts are still rising. Some nations have managed to “flatten” the death rate via protective measures such physical distancing, quarantine measures, and therapeutic management. The structure of the SARS-CoV-2 virus comprises of S proteins, M proteins, E proteins, hemagglutinin esterases, nucleocapsid proteins, and a 30-kb RNA genome. Viral proteases cleave these polyproteins and RNA-dependent polymerases replicate the genome. Currently, there are no effective therapies against this new disease. Numerous investigators are developing novel protease inhibitors, some of which have made it into clinical trials. Researchers are also attempting to develop a vaccine. In this review paper, we discuss the latest therapeutic developments against COVID-19. [Figure not available: see fulltext.]

    Original languageEnglish (US)
    Pages (from-to)4106-4116
    Number of pages11
    JournalMolecular Neurobiology
    Issue number10
    StatePublished - Oct 1 2020


    • HCQ
    • Protease inhibitor
    • Remdesivir
    • SARS-CoV-2
    • Vaccines

    ASJC Scopus subject areas

    • Neurology
    • Cellular and Molecular Neuroscience


    Dive into the research topics of 'Current Status of Multiple Drug Molecules, and Vaccines: An Update in SARS-CoV-2 Therapeutics'. Together they form a unique fingerprint.

    Cite this